<DOC>
	<DOCNO>NCT01697657</DOCNO>
	<brief_summary>This trial conduct Africa , Europe Oceania . The aim trial investigate whether insulin detemir combine insulin aspart compare NPH insulin combine insulin aspart could reduce frequency hypoglycaemic episode whilst maintain degree glycaemic control subject type 1 diabetes .</brief_summary>
	<brief_title>Frequency Hypoglycaemic Episodes During Treatment With Insulin Detemir Well Controlled Subjects With Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Isophane insulin , beef</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Isophane Insulin , Human</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<criteria>Type 1 diabetes Fasting cpeptide low limit normal fasting range Duration type 1 diabetes least 12 month Current treatment : Basal bolus regimen least 4 month intermediate longacting insulin , twice three time daily basal insulin 34 premeal insulin aspart lispro injection HbA1c maximum 9.0 % ( use Biorad Variant method ) Able willing perform selfmonitoring blood glucose Basal insulin requirement least 30 % total daily insulin dose BMI ( body Mass Index ) maximum 35 kg/m^2 Proliferative retinopathy maculopathy require acute treatment Total daily insulin dose 1.4 IU/kg/day Known unawareness hypoglycaemia Impaired hepatic function Impaired renal function Cardiac problem Uncontrolled , treated/untreated hypertension Known suspect allergy trial product relate product</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>